Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Biophytis S.A. (BPTSY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/31/2025: BPTSY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.18% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.32M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 14 | Beta 1.42 | 52 Weeks Range 2.77 - 18.80 | Updated Date 04/2/2025 |
52 Weeks Range 2.77 - 18.80 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -45.24 |
Earnings Date
Report Date 2025-04-07 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -65.37% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8869124 | Price to Sales(TTM) - |
Enterprise Value 8869124 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.42 | Shares Outstanding 1584320 | Shares Floating 5225816 |
Shares Outstanding 1584320 | Shares Floating 5225816 | ||
Percent Insiders - | Percent Institutions 0.21 |
Analyst Ratings
Rating 4 | Target Price 15 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biophytis S.A.
Company Overview
History and Background
Biophytis S.A. is a biotechnology company specializing in the development of therapeutics for age-related macular degeneration (AMD) and sarcopenia. Founded in 2006, it has focused on utilizing natural substances to combat age-related diseases.
Core Business Areas
- Age-Related Macular Degeneration (AMD) Program: Developing Saroglitazar Magnesium (BIO201) for the treatment of dry-AMD. This involves clinical trials and regulatory submissions.
- Sarcopenia Program: Developing Saroglitazar Magnesium (BIO101) for the treatment of sarcopenia. This includes clinical trials aimed at improving muscle function in older adults.
Leadership and Structure
Prof. Stanislas Veillet is the CEO. The company operates with a management team overseeing clinical development, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Saroglitazar Magnesium (BIO201): An orally administered treatment under development for dry-AMD. Currently in clinical trials. Market share is currently 0 as it is not yet approved. Competitors include Apellis Pharmaceuticals (SYK) with Syfovre, and Iveric Bio (ISEE).
- Saroglitazar Magnesium (BIO101): An orally administered treatment under development for sarcopenia. Currently in clinical trials. Market share is currently 0 as it is not yet approved. Competitors are limited as few approved treatments exist. Potential future competitors include companies developing muscle growth therapies.
Market Dynamics
Industry Overview
The biotechnology industry focused on age-related diseases is growing, driven by an aging global population. There is a significant unmet need for effective treatments for AMD and sarcopenia.
Positioning
Biophytis S.A. is positioned as a clinical-stage biotechnology company focusing on novel therapeutic approaches for AMD and sarcopenia. Its competitive advantage lies in its use of natural substances and unique drug formulations.
Total Addressable Market (TAM)
The TAM for AMD and sarcopenia treatments is significant. AMD market size is projected to reach billions of dollars. The sarcopenia market is also expected to grow substantially with the aging population. Biophytis S.A. aims to capture a portion of these markets with its pipeline.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches
- Clinical-stage pipeline
- Focus on unmet medical needs
- Experienced leadership team
Weaknesses
- Limited financial resources
- High reliance on clinical trial success
- Lack of approved products
- Small market capitalization
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Regulatory approval for BIO201 and BIO101
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- APLS
- ISEE
Competitive Landscape
Biophytis S.A. faces intense competition from established pharmaceutical companies with greater resources and approved products. Its success depends on demonstrating superior efficacy and safety in its clinical trials.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to being a clinical-stage company. Growth depends on successful clinical trials.
Future Projections: Future growth is contingent on regulatory approval and commercialization of BIO201 and BIO101. Analyst estimates are highly speculative at this stage.
Recent Initiatives: Recent initiatives include advancing clinical trials for BIO201 and BIO101, and securing funding for ongoing research.
Summary
Biophytis S.A. is a high-risk, high-reward clinical-stage biotech company focused on age-related diseases. Its success is heavily dependent on the outcomes of its clinical trials for BIO201 and BIO101. It faces challenges related to funding and competition but has the potential for significant growth if its therapies are approved. Investors should carefully evaluate the risks associated with clinical-stage companies.
Similar Companies
- APLS
- ISEE
Sources and Disclaimers
Data Sources:
- Biophytis S.A. Investor Relations
- SEC Filings
- Company Press Releases
- Analyst Reports (if available)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in clinical-stage biotech companies carries significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biophytis S.A.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | Chairman of the Board & CEO Mr. Stanislas Veillet Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 22 | Website https://www.biophytis.com |
Full time employees 22 | Website https://www.biophytis.com | ||
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.